A Single Dose Study Of PF-04620110 In Healthy Subjects
Status:
Completed
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
PF-04620110 is a novel compound proposed for the treatment of Type 2 diabetes mellitus. The
primary purpose of this trial is to evaluate the relative bioavailability of three different
oral dose formulations of PF-04620110.